Get started
Author

Zhilin Shen

Observed names: Z. Shen, Zhi-Lin Shen
ORCID: 0000-0003-4128-4524
Observed ORCID: 0000-0003-4128-4524
OpenAlex ID: A5068205782
TNF-α augments CXCL10/CXCR3 axis activity to induce Epithelial-Mesenchymal Transition in colon cancer cell
2021 · Zhengcheng Wang, Xiang Ao, et al. · International Journal of Biological Sciences · 89
PDF
Adjuvant icotinib versus observation in patients with completely resected EGFR-mutated stage IB NSCLC (GASTO1003, CORIN): a randomised, open-label, phase 2 trial
2023 · Wei Ou, Ning Li, et al. · EClinicalMedicine · 45
Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing
2021 · Yunpeng Yang, Jie Huang, et al. · Journal of Thoracic Oncology · 45
Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity
2022 · Chris Liang, Xiaobin Yuan, et al. · Molecular Therapy — Oncolytics · 37
PDF
Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study
2022 · Shun Lu, Yiping Zhang, et al. · Journal of Thoracic Oncology · 30
PDF
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory ALK ‐positive NSCLC from a phase II study
2024 · Jing Zheng, Tao Wang, et al. · 癌症：英文版 · 15
PDF
Safety and tolerability of oral vorolanib for neovascular (wet) age-related macular degeneration: a phase I, open-label study
2023 · Yunxia Gao, Fang Lu, et al. · Eye · 9
PDF
Ensartinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
2026 · Dongsheng Yue, Meijuan Huang, et al. · New England Journal of Medicine · 8
Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial
2024 · Shun Lu, Yiping Zhang, et al. · Lung Cancer · 6
Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China
2021 · Yang Wang, Xiaobin Yuan, et al. · Pharmacology · 5
A Retrospective Study of Ensartinib-Treated ALK -Positive Locally Advanced or Metastatic NSCLC Patients in China
2023 · Xiaobin Yuan, Yang Wang, et al. · Lung Cancer Management · 3
A phase I dose-escalation and dose-expansion study of tibremciclib, a novel CDK4/6 inhibitor, monotherapy and in combination with fulvestrant in HR-positive/HER2-negative advanced breast cancer
2025 · J. Zhang, R. Liu, et al. · ESMO Open · 1
PDF
Ensartinib in the treatment of anaplastic lymphoma kinase‐positive locally advanced or metastatic patients with lung squamous or adenosquamous carcinoma: A real‐world, retrospective study
2024 · Lieming Ding, Xiaobin Yuan, et al. · Asia-Pacific Journal of Clinical Oncology · 1
Application of the ESMO Magnitude of Clinical Benefit Scale to assess the clinical benefit of antibody drug conjugates in solid cancer: a systematic descriptive analysis of phase III and pivotal phase II trials
2024 · Lieming Ding, Xiaobin Yuan, et al. · BMJ Open · 1
Works count: 14
Citation count: 295
H-index: 8
I10-index: 6
Year
Topic
Type